Biomarkers Market Size, Share & Trends Analysis By Product, By Type, By Application, By disease indication By, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Biomarkers Market is projected to be worth USD 117.6 billion by 2030.
According to SPER Market Research, the Biomarkers Market is estimated to reach USD 117.6 billion by 2030 with a CAGR of 11.8%. Companion diagnostics, growing incidence of cancer globally, escalating funds & grants for biomarker research, and persistent innovations; these are the key factors acting as the fuel for the expansion of this market.
Impact of COVID-19 on the Biomarkers Market
Biomarkers play a vital role in the diagnosis of COVID-19. Patients with rigorous complications of COVID-19 have higher biomarkers level like cardiac troponin, renal biomarkers, lymphocytes, platelet count, C-reactive protein, serum amyloid A, and interleukin-6. Lymphocytes and platelet count is considerably lower in severe patients. To sustain COVID-19 research, the top players of this market developed assay and test kits. COVID-19 has a positive impact on this market expansion.
Scope of the report:
Market size available for years
2019-2030
Base year considered
2021
Forecast period
2022-2030
Segments covered
By Product, By Type, By Application, By Disease Indication, By Region
Geographies covered
North America, Europe, Asia Pacific, Latin America , Middle East, Africa
Companies Covered
Abbott Laboratories, Bio-Rad Laboratories, Inc., Charles River Laboratories, International, Inc., Enzo Biochem, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc.
Driver: increasing significance of companion diagnostics
Biomarkers, with the capability to spot drug target molecules play an important function in the development of companion diagnostics. Biomarkers & Companion diagnostics are important in the practice of medicine; this allows superior diagnosis, cure, and monitor numerous disease. These diagnostics are frequently used to identify patients apt to react well to certain drugs or treatment options, also used in combination with a specific drug. Accordingly, increase in the significance of companion diagnostics lead to escalation of this market.
Restraint: More capital investments and extended periods for biomarker development
The validation of the biomarkers development is a more time taking procedure, and costly.
Challenges: biomarker validation
Biomarkers validation is an expensive method, sensitive, inaccurate.
Opportunity: Personalized medicine
Biomarkers have a major role in the personalized medicine and companion diagnostics.
Due to demand for personalized medicine globally; offers enormous opportunities in this field.
Global Biomarkers Market, by Product:
Based on the Product, Biomarkers market is segmented as; Consumables, Services, Software.
Global Biomarkers Market, by Type:
Based on the Type, Biomarkers market is segmented as;Efficacy Biomarkers, Pharmacodynamics Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Biomarkers, Validation Biomarkers.
Global Biomarkers Market, by Application:
Based on the Application, Biomarkers market is segmented as; Diagnostics, Disease Risk Assessment, Drug Discovery & Development, Other Applications, Personalized Medicine.
Global Biomarkers Market, by Disease Indication:
Based on the Disease Indication, Biomarkers market is segmented as; Cancer by Test Type (Solid biopsy, Liquid Biopsy), Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Other Disease Indications.
Global Biomarkers Market, by Region:
North America owns the prime share of this market; it is due to the implementation of biomarkers in the diagnosis of diseases like cancer diagnosis, rising exploitation of biomarkers in personalized medicine, presence of big pharmaceutical companies, and adoption of strategies for the escalation of the market.
According to SPER Market Research, the Biomarkers Market is estimated to reach USD 117.6 billion by 2030 with a CAGR of 11.8%. Companion diagnostics, growing incidence of cancer globally, escalating funds & grants for biomarker research, and persistent innovations; these are the key factors acting as the fuel for the expansion of this market.
Impact of COVID-19 on the Biomarkers Market
Biomarkers play a vital role in the diagnosis of COVID-19. Patients with rigorous complications of COVID-19 have higher biomarkers level like cardiac troponin, renal biomarkers, lymphocytes, platelet count, C-reactive protein, serum amyloid A, and interleukin-6. Lymphocytes and platelet count is considerably lower in severe patients. To sustain COVID-19 research, the top players of this market developed assay and test kits. COVID-19 has a positive impact on this market expansion.
Scope of the report:
Market size available for years
2019-2030
Base year considered
2021
Forecast period
2022-2030
Segments covered
By Product, By Type, By Application, By Disease Indication, By Region
Geographies covered
North America, Europe, Asia Pacific, Latin America , Middle East, Africa
Companies Covered
Abbott Laboratories, Bio-Rad Laboratories, Inc., Charles River Laboratories, International, Inc., Enzo Biochem, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc.
Driver: increasing significance of companion diagnostics
Biomarkers, with the capability to spot drug target molecules play an important function in the development of companion diagnostics. Biomarkers & Companion diagnostics are important in the practice of medicine; this allows superior diagnosis, cure, and monitor numerous disease. These diagnostics are frequently used to identify patients apt to react well to certain drugs or treatment options, also used in combination with a specific drug. Accordingly, increase in the significance of companion diagnostics lead to escalation of this market.
Restraint: More capital investments and extended periods for biomarker development
The validation of the biomarkers development is a more time taking procedure, and costly.
Challenges: biomarker validation
Biomarkers validation is an expensive method, sensitive, inaccurate.
Opportunity: Personalized medicine
Biomarkers have a major role in the personalized medicine and companion diagnostics.
Due to demand for personalized medicine globally; offers enormous opportunities in this field.
Global Biomarkers Market, by Product:
Based on the Product, Biomarkers market is segmented as; Consumables, Services, Software.
Global Biomarkers Market, by Type:
Based on the Type, Biomarkers market is segmented as;Efficacy Biomarkers, Pharmacodynamics Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Biomarkers, Validation Biomarkers.
Global Biomarkers Market, by Application:
Based on the Application, Biomarkers market is segmented as; Diagnostics, Disease Risk Assessment, Drug Discovery & Development, Other Applications, Personalized Medicine.
Global Biomarkers Market, by Disease Indication:
Based on the Disease Indication, Biomarkers market is segmented as; Cancer by Test Type (Solid biopsy, Liquid Biopsy), Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Other Disease Indications.
Global Biomarkers Market, by Region:
North America owns the prime share of this market; it is due to the implementation of biomarkers in the diagnosis of diseases like cancer diagnosis, rising exploitation of biomarkers in personalized medicine, presence of big pharmaceutical companies, and adoption of strategies for the escalation of the market.
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact on the Biomarkers Market
4.4. Market Trends
5. GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
5.1. Consumables
5.2. Services
5.3. Software
6. GLOBAL BIOMARKERS MARKET, BY TYPE, 2019-2030 (USD MILLION)
6.1. Efficacy Biomarkers
6.2. Pharmacodynamics Biomarkers
6.3. Predictive Biomarkers
6.4. Prognostic Biomarkers
6.5. Safety Biomarkers
6.6. Surrogate Biomarkers
6.7. Validation Biomarkers
7. GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2019-2030 (USD MILLION)
7.1. Diagnostics
7.2. Disease Risk Assessment
7.3. Drug Discovery & Development
7.4. Other Applications
7.5. Personalized Medicine
8. GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2030 (USD MILLION)
8.1. Cancer by Test Type
8.1.1. Solid biopsy
8.1.2. Liquid Biopsy
8.2. Infectious Diseases
8.3. Immune Disorders
8.4. Neurological Disorders
8.5. Cardiovascular Disorders
8.6. Other Disease Indications
9. GLOBAL BIOMARKERS MARKET, BY REGION, 2019-2030 (USD MILLION)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. Rest of the Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Rest of Asia Pacific
9.4. Latin America
9.5. Middle East
9.6. Africa
10. COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Market Share Analysis, By Key Players
10.3. Competitive Scenario
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.2. Bio-Rad Laboratories, Inc.
11.3. Charles River Laboratories International, Inc.
11.4. Enzo Biochem, Inc.
11.5. Eurofins Scientific
11.6. F. Hoffmann-La Roche Ltd.
11.7. Merck KGaA
11.8. PerkinElmer, Inc.
11.9. QIAGEN N.V.
11.10. Thermo Fisher Scientific Inc
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact on the Biomarkers Market
4.4. Market Trends
5. GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
5.1. Consumables
5.2. Services
5.3. Software
6. GLOBAL BIOMARKERS MARKET, BY TYPE, 2019-2030 (USD MILLION)
6.1. Efficacy Biomarkers
6.2. Pharmacodynamics Biomarkers
6.3. Predictive Biomarkers
6.4. Prognostic Biomarkers
6.5. Safety Biomarkers
6.6. Surrogate Biomarkers
6.7. Validation Biomarkers
7. GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2019-2030 (USD MILLION)
7.1. Diagnostics
7.2. Disease Risk Assessment
7.3. Drug Discovery & Development
7.4. Other Applications
7.5. Personalized Medicine
8. GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2019-2030 (USD MILLION)
8.1. Cancer by Test Type
8.1.1. Solid biopsy
8.1.2. Liquid Biopsy
8.2. Infectious Diseases
8.3. Immune Disorders
8.4. Neurological Disorders
8.5. Cardiovascular Disorders
8.6. Other Disease Indications
9. GLOBAL BIOMARKERS MARKET, BY REGION, 2019-2030 (USD MILLION)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. Rest of the Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Rest of Asia Pacific
9.4. Latin America
9.5. Middle East
9.6. Africa
10. COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Market Share Analysis, By Key Players
10.3. Competitive Scenario
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.2. Bio-Rad Laboratories, Inc.
11.3. Charles River Laboratories International, Inc.
11.4. Enzo Biochem, Inc.
11.5. Eurofins Scientific
11.6. F. Hoffmann-La Roche Ltd.
11.7. Merck KGaA
11.8. PerkinElmer, Inc.
11.9. QIAGEN N.V.
11.10. Thermo Fisher Scientific Inc
